PLERIXAFOR ACCORD (Accord Healthcare Pty Ltd)
Product name
PLERIXAFOR ACCORD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
131 (255 working days)
Active ingredients
Plerixafor
Registration type
New generic medicine
Indication
Plerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise haematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma (MM).